These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1344465)

  • 1. [Prophylaxis and therapy of infections in allogenic bone marrow transplantation in patients with hematologic diseases].
    Pejin D; Pecić J; Patić V; Popović S; Dreher-Doroski H; Milutinović M; Uzurov V; Lenert P; Spasojević J; Gebauer E
    Med Pregl; 1992; 45(9-10):317-23. PubMed ID: 1344465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Allogenic bone marrow transplantation in acute leukemia].
    Kier P; Hinterberger W
    Wien Med Wochenschr; 1991; 141(9-10):221-4. PubMed ID: 1949849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplant infections: single center experience from the developing world.
    Ullah K; Raza S; Ahmed P; Chaudhry QU; Satti TM; Ahmed S; Mirza SH; Akhtar F; Kamal K; Akhtar FM
    Int J Infect Dis; 2008 Mar; 12(2):203-14. PubMed ID: 17920999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation in the treatment of hematologic diseases.
    Yee GC; McGuire TR
    Clin Pharm; 1985; 4(2):149-60. PubMed ID: 3886273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Allogenic transplantation of bone marrow in hematologic diseases. Preparation and completion of transplantation at the Hematology Clinic in Novi Sad].
    Pejin D; Popović S; Dokić M; Felle D; Stefanović N
    Acta Chir Iugosl; 1990; 37 Suppl 1():11-5. PubMed ID: 2109441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time of onset, viral load, relapse, and duration of active cytomegalovirus infection in bone marrow transplant outcomes.
    Habib K; Lamia T; Amel L; Abdelrahmen A; Saloua L; Hana E; Amine S; Bechir Z; Tarek BO; Assia BH
    Exp Clin Transplant; 2008 Mar; 6(1):67-73. PubMed ID: 18405248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of infection after bone marrow transplantation].
    Schmeiser T
    Fortschr Med; 1991 Feb; 109(6):155-7. PubMed ID: 1646147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indications for allogeneic and autologous bone marrow transplantation].
    Gmür J
    Schweiz Med Wochenschr; 1991 Apr; 121(14):488-92. PubMed ID: 1852073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A preliminary analysis of unrelated marrow transplantations facilitated by the Japan Marrow Donor Program (JMDP)].
    Okamoto S; Harada M; Kato S; Morishima Y; Imamura M; Tsuchiya S; Yamada Y; Kodo H; Hoshi Y; Tsuchida M
    Rinsho Ketsueki; 1995 Jun; 36(6):524-9. PubMed ID: 7643445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Indications, technique and risks in bone marrow transplantation in adulthood].
    Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W
    Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Favorable current prognosis after HLA-identical bone marrow transplantation for children with required severe aplastic anemia; evaluation of 30 years of bone marrow transplantation at the Leiden University Medical Center].
    van Steekelenburg M; van Weel-Sipman MH; Zwinderman AH; Hoogerbrugge PM; Vossen JM; Egeler RM
    Ned Tijdschr Geneeskd; 2002 Aug; 146(33):1542-6. PubMed ID: 12212502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic bone marrow transplantations at Huddinge Hospital and strategies to improve survival.
    Ringdén O; Aschan J; Boström L; Dahllöf G; Tollemar J; Paulin T; Gahrton G; Groth CG; Klaesson S; Lindquist R
    Clin Transpl; 1990; ():175-87. PubMed ID: 2103143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.